Your browser doesn't support javascript.
loading
Advance in drug treatment of autoimmune diseases / 中国药理学通报
Chinese Pharmacological Bulletin ; (12): 149-156, 2019.
Article de Zh | WPRIM | ID: wpr-857272
Bibliothèque responsable: WPRO
ABSTRACT
Autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, etc.) are diseases characterized by local or systemic abnormal inflammatory immune response. At present, the treatment drugs of autoimmune diseases mainly include nonsteroid anti-inflammatory drugs, steroid anti-inflammatory drugs and disease modifying anti-rheumatic drugs (chemical medicine, natural medicine and biological agents), etc. With the pathological mechanism of autoimmune diseases to be clarified deeply and the discovery of new drug targets, new biological agents targeting cytokines and cell surface molecules have been developed rapidly. In recent years, multiple small molecule drugs targeting Janus kinase/ signal transducers and activators of transcription signaling pathway have been developed and applied in clinic. Soft regulation of inflammatory immune response drugs are the drugs with anti-inflammatory and immunomodulatory effects, as well as less adverse reactions. To develop this type of drug will be a new strategy and one of the main directions for the treatment of autoimmune diseases. The research progress of medicines to treat autoimmune diseases has been reviewed in this paper.
Mots clés
Texte intégral: 1 Indice: WPRIM langue: Zh Texte intégral: Chinese Pharmacological Bulletin Année: 2019 Type: Article
Texte intégral: 1 Indice: WPRIM langue: Zh Texte intégral: Chinese Pharmacological Bulletin Année: 2019 Type: Article